Read more at NEJM August 31, 2022：Intradermal Vaccination for Monkeypox — Benefits for Individual and Public Health
DOI: 10.1056/NEJMp2211311
Despite limited clinical evidence, all available data suggest that intradermal administration of JYNNEOS will be as immunogenic as subcutaneous dosing for preventing monkeypox infection and illness, which leads us to favor intradermal use from both the individual and public health perspectives.
